OncoMatch/Clinical Trials/NCT05608213
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
Is NCT05608213 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Lenvatinib for hepatocellular carcinoma non-resectable.
Treatment: Lenvatinib — This study is conducted to evaluate the efficacy and safety of lenvatinib plus iodine-125 seed brachytherapy (Len-I) compared with lenvatinib (Len) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic therapy
Patients who received prior systemic therapy ... for HCC
Cannot have received: immunotherapy
Patients who received prior ... immunotherapy ... for HCC
Cannot have received: hepatic arterial infusion chemotherapy
Patients who received prior ... hepatic arterial infusion chemotherapy (HAIC) ... for HCC
Cannot have received: radiation therapy
Patients who received prior ... radiotherapy for HCC
Lab requirements
Blood counts
platelets <50×10^9/L [excluded]; prothrombin time prolongation ≥ 4s [excluded]
Liver function
Child-Pugh class A/B
Cardiac function
Severe organ (heart, lung, kidney) dysfunction [excluded]
Child-Pugh class A/B; Hematologic examination: platelets <50×10^9/L; Prothrombin time prolongation ≥ 4s; Severe organ (heart, lung, kidney) dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05608213 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy, immunotherapy, hepatic arterial infusion chemotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages